Wedbush Forecasts Xencor’s Q4 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR) – Investment analysts at Wedbush issued their Q4 2026 EPS estimates for shares of Xencor in a research note issued on Wednesday, May 7th. Wedbush analyst D. Nierengarten expects that the biopharmaceutical company will post earnings of ($0.81) per share for the quarter. Wedbush currently has a “Outperform” rating and a $31.00 target price on the stock. The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $32.73 million for the quarter, compared to the consensus estimate of $23.44 million. During the same period in the prior year, the firm posted ($1.11) EPS. The business’s revenue for the quarter was up 104.6% on a year-over-year basis.

XNCR has been the subject of a number of other reports. Wells Fargo & Company dropped their price target on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. William Blair assumed coverage on Xencor in a research note on Monday, April 21st. They issued an “outperform” rating for the company. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Finally, Barclays reduced their price target on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a research report on Thursday. Two analysts have rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Xencor Trading Down 5.2 %

Shares of NASDAQ:XNCR opened at $8.33 on Friday. The stock has a 50 day moving average of $10.73 and a 200 day moving average of $17.63. The company has a market cap of $592.70 million, a PE ratio of -2.60 and a beta of 0.99. Xencor has a 12-month low of $7.16 and a 12-month high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 508 shares during the period. KBC Group NV grew its stake in Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 813 shares in the last quarter. Sterling Capital Management LLC increased its holdings in Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,040 shares during the period. New York State Teachers Retirement System raised its position in Xencor by 2.1% during the 1st quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company’s stock valued at $631,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its holdings in shares of Xencor by 22.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 1,282 shares during the period.

Insider Activity at Xencor

In other news, EVP Nancy Valente sold 4,616 shares of Xencor stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the sale, the executive vice president now directly owns 49,169 shares in the company, valued at approximately $542,334.07. This trade represents a 8.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.76% of the stock is owned by company insiders.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.